Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer

PURPOSE: Cemiplimab is approved for the treatment of locally advanced basal cell carcinomas (BCC), although with mitigated results. We sought to interrogate the cellular and molecular transcriptional reprogramming underlying BCC resistance to immunotherapy. EXPERIMENTAL DESIGN: Here, we combined spa...

Descripción completa

Detalles Bibliográficos
Autores principales: Pich-Bavastro, Christine, Yerly, Laura, Di Domizio, Jeremy, Tissot-Renaud, Stéphanie, Gilliet, Michel, Kuonen, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472111/
https://www.ncbi.nlm.nih.gov/pubmed/37327314
http://dx.doi.org/10.1158/1078-0432.CCR-23-0219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472111/
https://www.ncbi.nlm.nih.gov/pubmed/37327314
http://dx.doi.org/10.1158/1078-0432.CCR-23-0219

Ejemplares similares